Expert blog

Oct. 26, 2016
References
  1. Breast cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 5, 2016.
  2. Hormone therapy for breast cancer. National Cancer Institute. http://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. Accessed Aug. 19, 2016.
  3. Pritchard KI. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer. http://www.uptodate.com/home. Accessed Aug. 19, 2016.
  4. Fareston (prescribing information). Bridgewater, N.J.: ProStrakan Inc.; 2012. http://www.fareston.com. Accessed Aug. 19, 2016.
  5. Arimidex (prescribing information). Wilmington, Del.: AstraZeneca; 2013. http://www.arimidex.com. Accessed Aug. 19, 2016.
  6. Aromasin (prescribing information). New York, N.Y.: Pfizer Inc.; 2016. http://www.aromasin.com. Accessed Aug. 19, 2016.
  7. Faslodex (prescribing information). Wilmington, Del.: AstraZeneca; 2016. http://www.faslodex.com. Accessed Aug. 19, 2016.
  8. Zoladex (prescribing information). Wilmington, Del.: AstraZeneca; 2016. http://www.zoladex.com. Accessed Aug. 19, 2016.
  9. Femara (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2014. http://www.femara.com. Accessed Aug. 19, 2016.
  10. AskMayoExpert. Breast cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  11. Ellis M, et al. Mechanisms of action of selective estrogen receptor modulators. http://www.uptodate.com/home. Accessed Sept. 12, 2016.
  12. Ibrance (prescribing information). Mission, Kan.: Pfizer Inc; 2016. http://www.ibrance.com. Accessed Sept. 12, 2016.
  13. Afinitor (prescribing information). East Hanover, N.J.: Novartis Pharmaceuticals Corporation; 2016. http://www.afinitor.com. Accessed Sept. 12, 2016.